Gilead Opts In On Multiple Arcus IO Candidates, Setting Up Combo Therapy Plans
Executive Summary
Gilead is licensing two anti-TIGIT candidates and a pair of adenosine pathway-targeted drugs. The firms will study various IO combo regimens, possibly including Gilead drugs like Trodelvy.
You may also be interested in...
Gilead Increases Investment In Arcus; Firms Abandon Chemo-Free Combo Study
With a $320m equity investment, Gilead will now own 33% of partner Arcus, which it said reinforces its optimism around the anti-TIGIT class for oncology.
Gilead Adds Inflammation Targets To Its 2020 R&D Collaboration With Arcus
Deal Snapshot: Already partnered on an anti-TIGIT drug and other immuno-oncology candidates, the firms will team up further on four targets in inflammatory disease.
Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030
At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.